Oaktree Acquisition Corp. III Life Sciences is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company intends to focus on the healthcare or healthcare-related industries, specifically targeting North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. It is sponsored by an affiliate of Oaktree Capital Management L.P. The management team includes Dr. Aman Kumar and Zaid Pardesi, who have prior experience with Oaktree’s previous special purpose acquisition companies that completed business combinations with Hims & Hers Health, Inc. and Alvotech. The company completed its initial public offering in October 2024 and has not yet selected a specific business combination target.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Shell Companies Homepage oaktreeacquisitioncorp.com/oac-iii
Sector Financial Services IR page —
Tags
blank check company, special purpose acquisition company, life sciences, healthcare, biopharmaceutical, medical devices, diagnostics, healthcare services, Oaktree Capital Management L.P., Hims & Hers Health Inc., Alvotech, Oaktree Acquisition Corp., Oaktree Acquisition Corp. II
Press page —

Metrics

Valuation  
Market cap $ 264.511M
Market cap (USD) $ 264.511M
P/E 61.02
PEG —
P/BV -27.50
P/S —
P/OCF -438.48
P/FCF -626.69
Dividend yield —
Turnover / mcap —
Returns  
ROE -107.7%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Assets 203.112M 195.251M
Net profit 7.289M 0
Free cash flow -422.079K —

Figure FY 2025 FY 2024
Share price 10.58 —
Price performance 12m 0.06 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 1.36M 1.43M
Cash flow detail
Operating cash flow (USD) — -422,079
Reported May 14, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

On October 23, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) issued 4,798,758 Class A ordinary shares, par value $0.0001 per share to Oaktree Acquisition Holdings III LS, LLC, a Cayman Islands limited liability company (the “Sponsor”) upon conversion (the “Conversion”) by the Sponsor of its 4,798,758 Class B ordinary shares, par value $0.0001 per. Following the Conversion, the Sponsor is holding 5,382,739 Class A ordinary shares (including 583,981 private placement shares included in the private placement units that the Sponsor purchased from OAC in connection with OAC’s initial public offering) and 1,000 Class B ordinary shares. The 4,798,758 Class A ordinary shares issued in connection with the Conversion are subject to the same restrictions as applied to the Class B ordinary shares before the Conversion, including, among other things, certain transfer restrictions, waiver of redemption rights and the obligation to vote in favor of an initial business combination as described in OAC’s final prospectus for its initial public offering.

Postponement of General Meeting to October 23, 2026 On October 2, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) filed a definitive proxy statement (the “Extension Proxy Statement”) for an extraordinary general meeting in lieu of an annual meeting of its shareholders to be held on October 16, 2026 (the “General Meeting”) to consider and act upon a proposal to extend the date by which OAC must complete an initial business combination (a “Business Combination”). On October 16, 2026, the extension committee of the board of directors of OAC (the “Board”) approved the postponement of the General Meeting, prior to the time at which it was scheduled to be held, to October 23, 2026 (such meeting, the “Rescheduled General Meeting”) in order to permit further solicitation and vote of proxies. The Rescheduled General Meeting will be held on October 23, 2026, at 10:00 a.m., Eastern Time, at the offices of Kirkland & Ellis LLP located at 601 Lexington Avenue, New York, NY 10022, and via a virtual meeting, or at such other time, on such other date and at such other place to which the meeting may be postponed or adjourned.

Preliminary Redemption Results On October 2, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) filed a definitive proxy statement (the “Extension Proxy Statement”) for an extraordinary general meeting in lieu of annual meeting of its shareholders to be held on October 16, 2026 to consider and act upon a proposal to extend (the “Extension”) the date by which OAC must complete an initial business combination (a “Business Combination”). As set forth in the Extension Proxy Statement, the deadline by which OAC public shareholders had to complete the procedures for electing to redeem their Class A ordinary shares, par value $0.0001 per share, of OAC (the “Class A ordinary shares”) was 5:00 p.m., Eastern Time, on October 14, 2026 (the “Redemption Deadline”). The number of Class A ordinary shares tendered for redemption prior to the Redemption Deadline was 13,326,977 Class A ordinary shares.

Prompts

Oaktree Acquisition Corp. III Life Sciences (ticker OACC), listed in United States.

ETFs Holding Oaktree Acquisition Corp. III Life Sciences

ETF Weight in ETF Shares Market value As of
SPAQ 5.31% 50,006 $ 535.564K Jun 30, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
OACC canonical Common share — US nasdaq 10.76 USD 2026-09-30
OACCU Unit — US nasdaq 10.89 USD 2026-09-30
OACCW Warrant — US nasdaq 1.00 USD 2026-09-30